Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/31/2002US20020161026 Combination therapies for the stimulation of bone growth
10/31/2002US20020161024 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1-one to treat an eye condition
10/31/2002US20020161023 Administering 2-(piperidin-2,6-dion-3-yl),4-amino-isoindolin-1,3-dione to treat an eye condition
10/31/2002US20020160980 Method of treating hepatitis delta virus infection
10/31/2002US20020160974 Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
10/31/2002US20020160973 Use of combretastatin A4 and its prodrugs as an immune enhancing therapy
10/31/2002US20020160972 Antisense compound with targeting and RNA cleaving moieties, preferably an imidazole functionality conjugated to the targeting oligonucleotide via linkers
10/31/2002US20020160970 Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes
10/31/2002US20020160962 Non-structural protein 3 (NS3), part of a hepatitis C virus protease necessary for polypeptide processing and viral replication; alpha-ketoamide compounds of given formula
10/31/2002US20020160961 Thyrotropin-Releasing Hormone (TRH) and a peptide of given formula, such as ipamorelin; treatment of wasting
10/31/2002US20020160960 Human leukocyte antigen/major histocompatibility complex (HLA); given amino acid sequence; useful to elicit an immune response against a desired antigen
10/31/2002US20020160959 Therapeutic compounds for ovarian cancer
10/31/2002US20020160957 Treating tumors
10/31/2002US20020160956 Pharmaceutical combination preparations containing erythropoietin and modified haemoglobins
10/31/2002US20020160955 Protein variants
10/31/2002US20020160954 Polynucleotides; Interphotoreceptor matrix component (IPMC) gene family; treating eye disorders
10/31/2002US20020160953 Mammalian glycoprotein hormone-1
10/31/2002US20020160952 Tri-peptide fusion proteins with domains that bind proteins with repeating glutamine residues; treating disorders such as Huntington's disease associated with expanded CAG repeats
10/31/2002US20020160951 Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
10/31/2002US20020160949 Nucleic acid encoding the receptor; use drug screening
10/31/2002US20020160948 Such as preventing or treating primary cancer cell growth
10/31/2002US20020160947 Synergistic method for prolonging allograft survival
10/31/2002US20020160946 Compounds having antifungal activity
10/31/2002US20020160945 Cyclase inhibiting parathyroid hormone antagonists or modulators and osteoporosis
10/31/2002US20020160944 Which contain multiple beta subunits of the hormones luteinizing hormone (LH), follicle stimulating hormone (FSH), chorionic gonadotropin (CG), and/or thyroid stimulating hormone coupled to the a subunit; use enhancing fertility
10/31/2002US20020160943 Tumor-activated prodrug compounds and treatment
10/31/2002US20020160942 Echinocandin/carbohydrate complexes
10/31/2002US20020160941 Treating compositions with lactoferrin
10/31/2002US20020160940 Modulation of endogenous gene expression in cells
10/31/2002US20020160938 At least one is a human or animal insulin analogue; coupled together with a diacid such as by reacting with suberic acid, bis(N-hydroxysuccinimidyl) ester
10/31/2002US20020160937 Human vitreous and pharmaceutical compositions
10/31/2002US20020160936 Hepatitis C virus envelope E2 protein (HCV E2); inhibiting the attachment of hepatitis C virus onto cells
10/31/2002US20020160499 For use in diagnosis, prophylaxis, and therapy of disorders associated with expression of serine carboxypeptidase
10/31/2002US20020160498 Can be used, for example, as target molecules for developing drugs against cancer
10/31/2002US20020160496 Diagnosis and treatment of disorders related to Hsp90 protein function
10/31/2002US20020160494 Tendon-inducing compositions
10/31/2002US20020160493 Serine/threonine phosphatase polynucleotides, polypeptides, and antibodies
10/31/2002US20020160492 Bovine aggrecanase-1
10/31/2002US20020160491 For diagnosis, prophylaxis and therapy of cancer, inflammation, neurological disorders and immune diseases and/or disorders
10/31/2002US20020160488 For therapy and prophylaxis of cell proliferation disorders, autoimmune/inflammatory disorders, and vesicle trafficking disorders
10/31/2002US20020160487 Testis specific transcription factor ZGCL-1
10/31/2002US20020160486 Human RNase H1 mutants
10/31/2002US20020160484 Central nervous system disorders therapy; genetic engineering
10/31/2002US20020160483 13245, a novel human myotonic dystrophy type protein kinase and uses therefor
10/31/2002US20020160478 Short peptides which selectively modulate the activity of protein kinases
10/31/2002US20020160477 CAF1-related protein
10/31/2002US20020160474 Adipocyte complement related protein zacrp11
10/31/2002US20020160456 Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
10/31/2002US20020160452 25206, a novel human short-chain dehydrogenase/reductase family member and uses thereof
10/31/2002US20020160451 Isolated nucleic acids; genetic engineering
10/31/2002US20020160448 Human c-Maf compositions and methods of use thereof
10/31/2002US20020160447 Ups (ugc)
10/31/2002US20020160446 Novel genes encoding proteins having prognostic diagnostic preventive therapeutic and other uses
10/31/2002US20020160430 Methods and compositions for obtaining mature dendritic cells
10/31/2002US20020160416 Receptor from TNF family
10/31/2002US20020160415 Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects
10/31/2002US20020160410 Amplification of nucleic acids
10/31/2002US20020160397 Measuring variations; calibration
10/31/2002US20020160393 Controlling gene expression in eukaryotic cells
10/31/2002US20020160388 Compositions and methods relating to lung specific genes and proteins
10/31/2002US20020160386 Methods of using transporter-like molecules to treat pain and pain-related disorders
10/31/2002US20020160384 Polypeptides; binding to antibodies
10/31/2002US20020160383 Use of nucleic acid analogues in diagnostics and analytical procedures
10/31/2002US20020160379 Gapped 2' modified oligonucleotides
10/31/2002US20020160374 Fusion protein; genetic engineering; binding to antibodies
10/31/2002US20020160365 Compositions and methods for the early diagnosis of ovarian cancer
10/31/2002US20020160355 Methods and reagents for modulating TGF-beta superfamily signalling
10/31/2002US20020160109 Microencapsulation of drugs by solvent exchange
10/31/2002US20020160039 Infusing lipid/alcohol solution directly into aqueous polymer solution; resulting liposome which may be incorporated with a pharmaceutical substance consists of multilamellar vesicles of average size of 1-8 microns
10/31/2002US20020160038 Cationic liposome containing cationic lipid, phosphatidylcholine and cholestrol; carrier for radiosensitizing tumor cells by administration of Human antisense c-raf-1 oligodeoxyribonucleotide
10/31/2002US20020160019 Providing peptide that bears a DR motif corresponding to a Class II HLA molecule, testing peptide for binding affinity to a Class II HLA DR molecule, whereupon an IC50 binding affinity is determined
10/31/2002US20020160017 Malaria vaccine
10/31/2002US20020160016 Modified surface antigen
10/31/2002US20020160015 Chemokine receptor able to bind to MCP-1, MIP-1 alpha and/or rantes and its uses
10/31/2002US20020160014 Cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells
10/31/2002US20020160010 Use of preparations containing anti-cd44 antibodies in the treatment of certain tumours and the suppression of immune reactions
10/31/2002US20020160008 Treatment of diabetes
10/31/2002US20020160005 Administering Shiga toxin or Shiga-like toxoid I or II as antigen to transgenic mouse having human genes, inducing immune response in mouse, isolating splenocytes from mouse following immune response, fusing splenocytes to myeloma cells
10/31/2002US20020160004 Antibodies against flt3-ligand
10/31/2002US20020160002 SseCKS gene encodes a substrate of protein kinase C that functions as both a mitogenic regulator as well as a tumor suppressor
10/31/2002US20020160001 That accompanies subarachnoid hemorrhage comprising administering as treatment or prevention an agent that inhibits vascular cell proliferation
10/31/2002US20020160000 PD-1, a receptor for B7-4, and uses therefor
10/31/2002US20020159998 Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
10/31/2002US20020159992 Antiangiogenic polypeptides and methods for inhibiting angiogenesis
10/31/2002US20020159991 Modulation of Abeta levels by beta-secretase BACE2
10/31/2002US20020159989 Peptide that interacts with thrombospondin 2 and inhibits matrix metalloproteinase 9 (MMP-9) activity, useful for treating diseases, such as cancer and arthritis
10/31/2002US20020159988 Lytic enzyme produced by bacteria being infected with a bacteriophage specific for such bacteria, useful for treating eye infection
10/31/2002US20020159987 Use of phage associated lytic enzymes for treating bacterial infections of the digestive tract
10/31/2002US20020159986 Administering to a patient a therapeutically effective amount of a bone morphogenetic protein-2 activity inhibitor: a polypeptide that binds specifically to the above protein
10/31/2002US20020159981 A cell population cultured ex-vivo in a culture medium under conditions permitting cells of cell population to proliferate and at the same time reducing capacity of cells in utilizing copper, hence expanded yet not further differentiated
10/31/2002US20020159977 Administering a recombinant adeno-associated virion into human suffering from hemophilia such that factor VIII nuclotide sequence are expressed at a level which provide therapeutically effective amount in the patient
10/31/2002US20020159976 An isolated polynucleotide comprising a nucleotide sequence present in Lactobacillus rhamnosus strain HN001 that encodes a polypeptide having atleast one enzymetic activity; genetic engineering
10/31/2002US20020159972 Nucleic acids encoding IL13 mutants
10/31/2002US20020159970 Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
10/31/2002US20020159969 A MUC-1 mucin (a high molecular weight glycoprotein) derivative, containing specific amino acid sequence and less than 60 amino acid in length, linked to a cytokine; clinically significant marker for cancers
10/31/2002US20020157677 Insulin delivery enhanced by coached breathing
10/31/2002DE10217066A1 Composition useful for treatment of central nervous system disorders, e.g. Alzheimer's disease comprises modulator of neuron-specific calcium sensor-1
10/31/2002DE10120627A1 Verwendung von Phyllanthusbestandteilen zur Behandlung oder Prophylaxe von Infekten durch Hepatitis B-Viren Use of Phyllanthus for the treatment or prophylaxis of infections caused by hepatitis B viruses
10/31/2002DE10118452A1 Nukleinsäuresequenzen von Hyperplasien und Tumoren der Schilddrüse Nucleic acid sequences of hyperplasias and tumors of the thyroid
10/31/2002CA2681952A1 Drug delivery matrices to enhance wound healing
1 ... 1966 1967 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1979 1980 1981 1982 1983 1984 1985 1986 ... 3163